Rising Prevalence of NASH Drives Non-Alcoholic Steatohepatitis (NASH) Market Growth According to our new research study on "Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Application, and Sales Channel," the market is expected to grow from US$ 1,631.92 million in 2021 to US$ 24,266.81 million by 2028; it is estimated to grow at a CAGR of 47.1% from 2021 to 2028. The report highlights the major factors driving the market, and prominent players and their developments in the market. The growth of the non-alcoholic steatohepatitis (NASH) market is mainly driven by the rising prevalence of NASH and increasing initiatives for the awareness of NASH. However, the lack of established guidelines for the diagnosis and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the market growth.

NASH is a potentially fatal illness that causes extensive scarring and cirrhosis of the liver. NAFLD is the most common chronic liver disease globally. NASH is a progressive form of NAFLD, which is gradually becoming the major cause of end-stage liver diseases and liver transplantation. According to the data published by the Global Liver Institute, NASH was termed as an epidemic on June 12, 2019. It affects over ~115 million people, and 357 million people are expected to be affected by this condition by 2030. Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH; more than ~70% of people are obese, ~75% have type 2 diabetes, and 20-80% have hyperlipidemia worldwide. NASH, if left untreated, can progress to cirrhosis and liver cancer, and raise the need for a liver transplant.

As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. ~25% of adults in the US have been estimated to have NAFLD, of which ~20% have NASH, i.e., 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% from 2015 to 2030 and NASH is predicted to become the major cause of liver transplantation in the US during 2020-2025. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease till 2030. As per the study, the prevalence of NAFLD and NASH cases is expected to increase by 21% and 63%, respectively, resulting in 33.5% and 27% prevalence rates, respectively, in adults.

Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences. Thus, the growing prevalence of NASH drives the non-alcoholic steatohepatitis (NASH) market.

The non-alcoholic steatohepatitis (NASH) market, by product, is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market from 2021 to 2028. Further, the selonsertib & cenicriviroc segment is anticipated to register the highest CAGR of 73.3% in the market during the forecast period. Selonsertib is an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. It is under investigation in clinical trial NCT03053050-Safety and Efficacy of Selonsertib in Adults with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Cenicriviroc (CVC) is a potent chemokine 2 and 5 receptor antagonist that is currently being developed for the treatment of liver fibrosis in individuals with NASH. Various research studies and clinical trials are being conducted worldwide for selonsertib and CVC, which are expected to drive the market during the forecast period.

Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings are among the leading companies operating in the non-alcoholic steatohepatitis (NASH) market. Product launches, product approvals, mergers and acquisitions, and market initiatives are a few of the major strategies adopted by the companies in this market. For instance, in January 2022, Siemens Healthineers announced the launch of Enhanced Liver Fibrosis (ELF) Test in the US. This is the first time the test was made commercially available in the country, following the de novo marketing authorization from the US Food and Drug Administration (FDA) in August 2021.

The report segments the non-alcoholic steatohepatitis (NASH) market as follows:

The non-alcoholic steatohepatitis (NASH) market is segmented on the basis of product, application, sales channel, and geography. Based on product, the market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. Based on application, the non-alcoholic steatohepatitis (NASH) market is bifurcated into treatment and diagnosis. Based on sales channel, the non-alcoholic steatohepatitis (NASH) market is segmented into hospital pharmacy, retail pharmacy, and online provider. By geography, the non-alcoholic steatohepatitis (NASH) market is segmented as North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com